AI Proteins
Boston
About AI Proteins
Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-enabled design and a high-throughput drug discovery platform, AI Proteins creates de novo miniproteins optimized for a variety of therapeutic applications. Partnered with leading biopharmaceutical companies, AI Proteins continues to pursue collaborations across a wide variety of therapeutic areas in addition to advancing its internal pipeline. The AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND-enabling studies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $10K – $50K
- Total funding: $79.4M
- Funding stage: Early Stage Venture
- Last round: Series A (Nov 2025)
- Website: aiproteins.com
- Phone: [email protected]
Industries & Categories
Artificial Intelligence (AI), Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/ai-proteins-18120 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.